Q32 Bio Inc
QTTB1.881USD
-0.119-5.95%
交易中 （美东）报价延迟15分钟
22.94M总市值
亏损市盈率 TTM
关于 Q32 Bio Inc 公司
Q32 Bio Inc. 是一家临床阶段的生物技术公司。该公司致力于开发针对先天和适应性免疫系统强效调节剂的生物疗法，以重新平衡自身免疫和炎症疾病中的免疫力。其主要项目专注于 IL-7/TSLP 受体途径和补体系统，解决免疫失调问题，帮助患者重新掌控自己的生活。其适应性免疫项目 bempikibart (ADX-914) 是一种完全人源抗 IL-7Ra 抗体，可重新调节适应性免疫功能，用于治疗自身免疫性疾病。它正在两项 II 期试验中进行评估，用于治疗特应性皮炎和斑秃。其先天免疫项目 ADX-097 基于一个平台，该平台能够对补体系统进行组织靶向调节，而无需长期全身阻断。该公司已在健康志愿者中完成了 ADX-097 的首次人体 I 期递增剂量临床研究。
公司简介
公司代码QTTB
公司名称Q32 Bio Inc
上市日期Mar 28, 2018
CEOMs. Jodie Pope Morrison
员工数量42
证券类型Ordinary Share
年结日Mar 28
公司地址830 Winter Street
城市WALTHAM
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编02451
电话17819990232
网址https://www.q32bio.com/
公司代码QTTB
上市日期Mar 28, 2018
CEOMs. Jodie Pope Morrison
公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
5.43K
--
Dr. David S. Grayzel, M.D.
Dr. David S. Grayzel, M.D.
Independent Director
Independent Director
--
--
Dr. Shelia M. Violette, Ph.D.
Dr. Shelia M. Violette, Ph.D.
Chief Scientific Officer, President of Research
Chief Scientific Officer, President of Research
--
--
Dr. Bill Lundberg, M.D.
Dr. Bill Lundberg, M.D.
Independent Director
Independent Director
--
--
Ms. Jodie Pope Morrison
Ms. Jodie Pope Morrison
Chief Executive Officer, Director
Chief Executive Officer, Director
--
-100.00%
Mr. Lee H. Kalowski
Mr. Lee H. Kalowski
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Diyong Xu
Mr. Diyong Xu
Independent Director
Independent Director
--
--
Dr. Isaac Manke
Dr. Isaac Manke
Independent Director
Independent Director
--
--
Ms. Mary T. Thistle, CPA
Ms. Mary T. Thistle, CPA
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
5.43K
--
Dr. David S. Grayzel, M.D.
Dr. David S. Grayzel, M.D.
Independent Director
Independent Director
--
--
Dr. Shelia M. Violette, Ph.D.
Dr. Shelia M. Violette, Ph.D.
Chief Scientific Officer, President of Research
Chief Scientific Officer, President of Research
--
--
Dr. Bill Lundberg, M.D.
Dr. Bill Lundberg, M.D.
Independent Director
Independent Director
--
--
Ms. Jodie Pope Morrison
Ms. Jodie Pope Morrison
Chief Executive Officer, Director
Chief Executive Officer, Director
--
-100.00%
Mr. Lee H. Kalowski
Mr. Lee H. Kalowski
President, Chief Financial Officer
President, Chief Financial Officer
--
--
收入明细
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
暂无数据
地区USD
名称
营收
占比
United States
0.00
0.00%
业务
地区
暂无数据
股东统计
更新时间: 6月4日 周三
更新时间: 6月4日 周三
持股股东
股东类型
持股股东
持股股东
占比
OrbiMed Advisors, LLC
18.47%
Atlas Venture
17.15%
Abingworth Management Limited
9.04%
Acorn Capital Advisors, LLC
6.59%
Monaco asset management S.A.M.
4.14%
Other
44.61%
持股股东
持股股东
占比
OrbiMed Advisors, LLC
18.47%
Atlas Venture
17.15%
Abingworth Management Limited
9.04%
Acorn Capital Advisors, LLC
6.59%
Monaco asset management S.A.M.
4.14%
Other
44.61%
股东类型
持股股东
占比
Venture Capital
28.82%
Investment Advisor
20.89%
Private Equity
18.47%
Corporation
5.92%
Investment Advisor/Hedge Fund
4.24%
Individual Investor
0.65%
Research Firm
0.61%
Hedge Fund
0.25%
Bank and Trust
0.10%
Other
20.05%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
211
9.76M
80.01%
-4.87M
2025Q1
223
10.26M
84.16%
-4.38M
2024Q4
223
11.35M
93.20%
-1.04M
2024Q3
208
11.60M
102.62%
+2.77M
2024Q2
197
10.02M
90.20%
+1.83M
2024Q1
230
9.37M
85.14%
+7.24M
2023Q4
242
1.68M
52.16%
-377.72K
2023Q3
262
1.62M
50.50%
-460.61K
2023Q2
275
1.63M
50.84%
-543.11K
2023Q1
291
1.72M
53.55%
-518.81K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
OrbiMed Advisors, LLC
2.25M
18.47%
--
--
Mar 31, 2025
Atlas Venture
2.09M
17.15%
--
--
Mar 31, 2025
Abingworth Management Limited
1.10M
9.04%
--
--
Mar 31, 2025
Acorn Capital Advisors, LLC
803.42K
6.59%
--
--
Mar 31, 2025
Monaco asset management S.A.M.
505.45K
4.14%
-69.36K
-12.07%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
412.40K
3.38%
-8.68K
-2.06%
Mar 31, 2025
ARCH Venture Partners
320.48K
2.63%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
309.21K
2.54%
-7.36K
-2.32%
Mar 31, 2025
Pfizer Inc
277.78K
2.28%
--
--
Mar 31, 2025
Sanofi SA
244.08K
2%
--
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
DFA Dimensional US Core Equity Market ETF
0%
Proshares Ultra Russell 2000
0%
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
Avantis US Small Cap Equity ETF
0%
Vanguard US Minimum Volatility ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Goldman Sachs Innovate Equity ETF
0%
Fidelity Enhanced Small Cap ETF
0%
iShares Russell 2000 ETF
0%
查看更多
DFA Dimensional US Core Equity Market ETF
占比0%
Proshares Ultra Russell 2000
占比0%
Global X Russell 2000 ETF
占比0%
ProShares Hedge Replication ETF
占比0%
Avantis US Small Cap Equity ETF
占比0%
Vanguard US Minimum Volatility ETF
占比0%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
Goldman Sachs Innovate Equity ETF
占比0%
Fidelity Enhanced Small Cap ETF
占比0%
iShares Russell 2000 ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Mar 20, 2024
Merger
18<1
Mar 20, 2024
Merger
18<1
Mar 20, 2024
Merger
18<1
Mar 20, 2024
Merger
18<1
公告日期
类型
比率
Mar 20, 2024
Merger
18<1
Mar 20, 2024
Merger
18<1
Mar 20, 2024
Merger
18<1
Mar 20, 2024
Merger
18<1
